Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:AMLX NASDAQ:KYMR NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.64$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsAMLXAmylyx Pharmaceuticals$14.83-7.7%$15.35$4.20▼$18.60$1.65B-0.111.23 million shs673,063 shsKYMRKymera Therapeutics$84.21-2.4%$84.38$28.06▼$103.00$6.93B2.06691,525 shs213,537 shsQGENQiagen$33.42-3.0%$41.23$33.17▼$57.81$6.90B0.642.30 million shs986,693 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.31%+71.90%+118.08%AMLXAmylyx Pharmaceuticals-2.25%+2.95%+1.52%+23.63%+245.38%KYMRKymera Therapeutics+4.29%+5.83%+1.16%+13.59%+201.91%QGENQiagen+1.39%+2.53%-15.53%-32.67%-22.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.64$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsAMLXAmylyx Pharmaceuticals$14.83-7.7%$15.35$4.20▼$18.60$1.65B-0.111.23 million shs673,063 shsKYMRKymera Therapeutics$84.21-2.4%$84.38$28.06▼$103.00$6.93B2.06691,525 shs213,537 shsQGENQiagen$33.42-3.0%$41.23$33.17▼$57.81$6.90B0.642.30 million shs986,693 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.31%+71.90%+118.08%AMLXAmylyx Pharmaceuticals-2.25%+2.95%+1.52%+23.63%+245.38%KYMRKymera Therapeutics+4.29%+5.83%+1.16%+13.59%+201.91%QGENQiagen+1.39%+2.53%-15.53%-32.67%-22.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideAMLXAmylyx Pharmaceuticals 2.77Moderate Buy$23.0055.09% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1040.24% UpsideQGENQiagen 2.50Moderate Buy$47.0940.90% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, QGEN, ACLX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026ACLXArcellx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.004/29/2026QGENQiagen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$60.00 ➝ $45.004/29/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $38.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53AMLXAmylyx PharmaceuticalsN/AN/AN/AN/A$2.78 per shareN/AKYMRKymera Therapeutics$39.21M176.66N/AN/A$18.72 per share4.50QGENQiagen$2.09B3.30$3.35 per share9.99$17.89 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%5/7/2026 (Estimated)AMLXAmylyx Pharmaceuticals-$144.74M-$1.55N/AN/AN/AN/A-57.52%-52.17%5/7/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/AQGENQiagen$424.88M$2.0216.6012.203.3820.33%14.56%8.62%N/ALatest AMLX, QGEN, ACLX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ACLXArcellx-$1.13N/AN/AN/A$6.07 millionN/A5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/6/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$499.20 million$492.32 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/3/2026Q4 2025AMLXAmylyx Pharmaceuticals-$0.31-$0.30+$0.01-$0.30($0.05) millionN/A2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$1.026.33%N/AN/A N/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.260.75%N/A12.87%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44AMLXAmylyx PharmaceuticalsN/A14.2714.27KYMRKymera TherapeuticsN/A10.8110.81QGENQiagen0.443.903.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AMLXAmylyx Pharmaceuticals95.84%KYMRKymera TherapeuticsN/AQGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AMLXAmylyx Pharmaceuticals12.30%KYMRKymera Therapeutics16.01%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableAMLXAmylyx Pharmaceuticals200111.09 million97.42 millionOptionableKYMRKymera Therapeutics17082.26 million69.09 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableAMLX, QGEN, ACLX, and KYMR HeadlinesRecent News About These CompaniesQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing2 hours ago | finance.yahoo.comQGEN SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Qiagen for Possible Securities Law Violations4 hours ago | globenewswire.comQiagen: Q1 Earnings SnapshotMay 6 at 11:51 PM | stamfordadvocate.comSQiagen (QGEN) Q1 Earnings and Revenues Lag EstimatesMay 6 at 10:51 PM | zacks.comQiagen (QGEN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 6 at 10:30 PM | zacks.comLevi & Korsinsky Investigates Qiagen N.V. (QGEN) Over Potential Securities Fraud AllegationsMay 6 at 7:20 PM | newsfilecorp.comNQGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law FirmMay 6 at 6:31 PM | globenewswire.comQIAGEN Reports Full Results for Q1 2026May 6 at 4:05 PM | businesswire.comQiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)May 6 at 9:00 AM | prnewswire.comVanguard Group Inc. Purchases 118,135 Shares of Qiagen N.V. $QGENMay 6 at 8:14 AM | marketbeat.comQiagen (QGEN) Gets a Buy from DZ BANK AGMay 5 at 10:47 PM | theglobeandmail.comBrokerages Set Qiagen N.V. (NYSE:QGEN) PT at $53.64May 4 at 4:08 AM | americanbankingnews.comQiagen Cuts 2026 Outlook as QuantiFERON Immigration Testing Slumps Despite EPS MatchMay 3, 2026 | marketbeat.comQiagen (NYSE:QGEN) Upgraded at Zacks ResearchMay 2, 2026 | americanbankingnews.comHow The Qiagen (QGEN) Investment Story Is Shifting As Analysts Rework Their AssumptionsMay 1, 2026 | finance.yahoo.comQiagen (NYSE:QGEN) Upgraded by Zacks Research to "Hold" RatingMay 1, 2026 | marketbeat.comOngoing Investigation into Qiagen N.V. (QGEN): Contact Levi & Korsinsky About Potential FraudApril 30, 2026 | newsfilecorp.comNQiagen (NYSE:QGEN) Price Target Lowered to $45.00 at JPMorgan Chase & Co.April 30, 2026 | americanbankingnews.comQiagen Sets Date for Publication of 2025 Annual Financial ReportApril 30, 2026 | theglobeandmail.comBaird upgrades Qiagen NV (QGEN)April 30, 2026 | msn.comRobert W. Baird Upgrades Qiagen (NYSE:QGEN) to Strong-BuyApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMLX, QGEN, ACLX, and KYMR Company DescriptionsArcellx NASDAQ:ACLX$115.07 0.00 (0.00%) As of 04/28/2026Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Amylyx Pharmaceuticals NASDAQ:AMLX$14.83 -1.23 (-7.66%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Kymera Therapeutics NASDAQ:KYMR$84.21 -2.05 (-2.38%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Qiagen NYSE:QGEN$33.42 -1.02 (-2.96%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
